Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basic Insulin Treatment by Community Doctors for Type 2 Diabetes
NCT04553380Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoints: Time to achieve target fasting blood glucose at 3 months, Decrease of Hemoglobin A1c at 3 months and 1 more. Status: unknown.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04553380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553380.